RTI-336

RTI-336

RTI-336 is a tropane derivative drug developed by the Research Triangle Institute (RTI), which acts as a potent and selective dopamine reuptake inhibitor (DRI). It is part of the larger RTI-31 series of tropanes.

History

RTI-336 was developed as part of the RTI-31 series, a group of compounds derived from the natural alkaloid cocaine. The RTI-31 series was developed in an attempt to create a drug with the stimulant properties of cocaine, but without its addictive potential. RTI-336 was one of the most successful compounds in this series, showing a high selectivity for the dopamine transporter over the other monoamine transporters.

Pharmacology

RTI-336 is a potent and selective DRI, meaning it increases the levels of the neurotransmitter dopamine in the brain by blocking its reuptake into neurons. This results in increased dopamine activity, which is associated with increased alertness, attention, and energy. However, unlike cocaine, RTI-336 does not have significant activity at the serotonin or norepinephrine transporters, which is believed to reduce its potential for addiction.

Potential Uses

RTI-336 has been investigated for potential use in the treatment of cocaine addiction. In animal studies, it has been shown to reduce cocaine self-administration, suggesting it could be used to help individuals reduce or quit their cocaine use. However, as of now, it has not been approved for this use in humans.

See Also

• Dopamine reuptake inhibitor
• Research Triangle Institute
• RTI-31

‎

‎